Other

Zalvac Ab

Staffan Normark

Thomas Boren

Anna Arnqvist

Dag Ilver

Birgitta Henriques Normark

Arne Olsen

Mario Codemo

Sandra Muschiol

Federico Iovino

Sun Nyunt Wai

Ana Rita Narciso

Peter Mellroth

An immunogenic composition comprising bacterial membrane vesicles (MVs) comprising a streptococcal MalX antigen and/or a streptococcal PrsA antigen, characterized in that the MVs do not comprise an immunogenic amount of a streptococcal PspA antigen. The membrane vesicles may be artificial membrane particles. Medical uses of the composition in particular for immunization against pneumococcal disease, and methods of manufacturing the composition.

Streptococcal vaccines

An isolatedmembrane vesicle microparticle (MP), wherein said MP comprises: the protein Ply at the level of ≥0.070 μg/μg total protein in the MP; and/or the protein LytA at the level of ≥0.070 μg/μg total protein in the MP; and/or the protein PspC at the level of ≥0.130 μg/μg total protein in the MP; and/or the protein RrgB at the level of ≥0.020 μg/μg total protein in the MP. Compositions comprising such MPs. Uses thereof in particular in immunization, as well as methods of manufacture thereof.

Microparticles fromas vaccine antigens

A novelblood group antigen binding (BAB) adhesin protein was isolated and purified, whereby said protein or fractions thereof bind specifically to fucosylated blood group antigens. The protein sequence of said adhesin is disclosed in this application. Simultaneously the DNA sequences for two genes, babA and babB, producing highly similar proteins, are disclosed. Said adhesin and/or DNA is useful for diagnose and therapy and/or prophylaxis directed againstinduced infections, e.g. gastritis and acid peptic disease, i.e. active vaccination. A new immunoglobulin composition, which exhibits specific activity to a Lewisantigen bindingadhesin, or preferably, monoclonal and/or polyclonal antibodies to said adhesin offer a new and more efficient method of treatment and/or prevention of gastrointestinal diseases, caused byor otherspecies, i.e. passive vaccination.

[object Object]

A novel blood group antigen binding (BAB) adhesin protein was isolated and purified, whereby said protein or fractions thereof bind specifically to fucosylated blood group antibodies. Said adhesin has a molecular weight of about 73.5 kDa and the N-terminal sequence for the adhesin and the corresponding DNA show homologies between different strains of Said adhesin and/or DNA is useful for diagnose and therapy and/or profylax directed against induced infections, e.g. gastritis and acid peptic disease.

Helicobacter pylori adhesin binding group antigen

A novel bacterial blood group antigen binding (BAB) adhesin protein was isolated and purified, whereby said protein or fractions thereof bind specifically to fucosylated blood group antibodies. The protein sequence of said adhesin is disclosed in this application. Simultaneously the DNA sequences for two genes, babA and babB, producing highly similar proteins, are disclosed. Said adhesin and/or DNA is useful for diagnose and therapy and/or profylax directed against induced infections, e.g. gastritis and acid peptic disease.

Blood group antigen binding protein and corresponding agents

The present invention relates to a new fibronectin binding protein from E. coli in the form of a curli pili. a new recombinant hybrid-DNA-molecule comprising a nucleotide sequence from E. coli coding for a protein or polypeptide having fibronectin binding properties. (FIG. 4).

Growing community of inventors

Stockholm, Sweden

Staffan Normark